Abstracts Archive - Page 915 of 2425 - ACR Meeting Abstracts

Abstract Number: 2350 • 2019 ACR/ARP Annual Meeting
Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis
Jeffrey Curtis¹, Fenglong Xie ², Cynthia Crowson ³, Brent Mabey ⁴, Darl Flake ⁴, Richard Bamford ⁴, Cheryl Chin ⁴, Eric Sasso ⁵, Elena Hitraya ⁵, Alexander Gutin ⁴ and Jerry Lanchbury ⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Mayo Clinic Rochester, Rochester, ⁴Myriad Genetics, Inc, South San Francisco, CA, ⁵Crescendo Bioscience, South San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) patients are at elevated risk for cardiovascular (CV) events, but efficient risk stratification based on CV prediction models is not part…
Abstract Number: 2351 • 2019 ACR/ARP Annual Meeting
Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
Jeffrey Curtis¹, Yong Lin ², Karthinathan Thangavelu ³, Marina Stanislav ⁴, Gregory St John ⁵, Antonio Gómez-Centeno ⁶, Carlo Selmi ⁷, Thomas Huizinga ⁸, José Antonio Maldonado-Cocco ⁹, Marwan Bukhari ¹⁰ and Frank Buttgereit ¹¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Bridgewater, NJ, ³Sanofi Genzyme, Boston, MA, ⁴V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁷Humanitas Research Hospital, University of Milan, Milan, Italy, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Buenos Aires University School of Medicine, Buenos Aires, Argentina, ¹⁰Lancaster University Medical School, Lancaster, United Kingdom, ¹¹Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The EXTEND open-label extension study (NCT01146652) is collecting data on long-term treatment of RA with sarilumab as monotherapy and in combination with conventional synthetic…
Abstract Number: 2352 • 2019 ACR/ARP Annual Meeting
Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis
Andrew J. Klink ¹, Bela Bapat ¹, Jill Kaufman ², Francis Lobo ³, Xue Han³, Leticia Ferri ³, Rick Szymialis ³, Tayla Poretta ³ and Bruce Feinberg ¹, ¹Cardinal Health Specialty Solutions, Dublin, OH, ²Cardinal Health Specialty Solutions, Dublin, ³Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: Distinct subgroups of RA are being identified by clinical, biochemical, and genomic markers. ACPA positivity is one such biomarker associated with a clinical profile…
Abstract Number: 2353 • 2019 ACR/ARP Annual Meeting
ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices
Bela Bapat ¹, Andrew J. Klink ¹, Jill Kaufman ², Francis Lobo ³, Xue Han³, Leticia Ferri ³, Rick Szymialis ³, Tayla Poretta ³ and Bruce Feinberg ¹, ¹Cardinal Health Specialty Solutions, Dublin, OH, ²Cardinal Health Specialty Solutions, Dublin, ³Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: Research is redefining RA as a heterogeneous group of diseases distinguished by clinical, biochemical, and genomic markers. ACPA positivity is one such biomarker associated…
Abstract Number: 2354 • 2019 ACR/ARP Annual Meeting
Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis
Helen Gosselt¹, Maxime Verhoeven ², Maurits de Rotte ³, Saskia Pluijm ⁴, Gerrit Jansen ⁵, Janneke Tekstra ², Sandra Heil ⁶, Floris Lafeber ², Mieke Hazes* ⁷ and Robert de Jonge* ⁸, ¹Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands and Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Amsterdam, Netherlands, ²UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ³Amsterdam UMC, Amsterdam Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Prinses Máxima Centre for Paediatric Oncology, Department of Paediatric Oncology Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Amsterdam UMC, VU Medical Center, Amsterdam Rheumatology and immunology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁶Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Erasmus MC, University Medical Center Rotterdam, Department of Rheumatology, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁸Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Methotrexate (MTX) constitutes first-line therapy in rheumatoid arthritis (RA). However, up to 40% of RA patients do not benefit from MTX therapy. To restrain…
Abstract Number: 2355 • 2019 ACR/ARP Annual Meeting
Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis
Thao Nguyen¹, Ingrid Hokstad ², Gia Deyab ³, Tom Eirik Mollnes ⁴, Stefan Agewall ⁴, Morten Fagerland ⁴, Gro Eilertsen ⁵, Mark Feinberg ⁶, Knut Mikkelsen ², Øystein Førre ⁴ and Ivana Hollan ⁷, ¹Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Oppland, Norway, ³Innlandet Hospital Trust, Bærum, Akershus, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵The Artic University of Norway, Tromsø, Norway, ⁶Harvard Medical School and Brigham and Women´s Hospital, Boston, Boston, MA, ⁷Lillehammer Hospital for Rheumatic Diseases and Brigham and Women’s Hospital, Boston, Lillehammer, Oppland, Norway
Background/Purpose: Inflammation and immune dysregulation appear to significantly contribute to increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). The complement system is a…
Abstract Number: 2356 • 2019 ACR/ARP Annual Meeting
Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Thao Nguyen¹, Gia Deyab ², Morten Fagerland ³, Stefan Agewall ³, Gro Eilertsen ⁴, Mark Feinberg ⁵, Knut Mikkelsen ⁶, Øystein Førre ³ and Ivana Hollan ⁷, ¹Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Innlandet Hospital Trust, Bærum, Akershus, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴The Artic University of Norway, Tromsø, Norway, ⁵Harvard Medical School and Brigham and Women´s Hospital, Boston, Boston, MA, ⁶Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Oppland, Norway, ⁷Lillehammer Hospital for Rheumatic Diseases and Brigham and Women’s Hospital, Boston, Lillehammer, Oppland, Norway
Background/Purpose: Patients with rheumatoid arthritis (RA) are predisposed to impaired cardiac function and heart failure (HF). While the pathophysiology has not been fully elucidated yet,…
Abstract Number: 2357 • 2019 ACR/ARP Annual Meeting
Methotrexate Liver Toxicity in a Large Randomized Controlled Trial
Daniel Solomon¹, Nina Paynter ², Anna Rutherford ², Robert Glynn ³, Jean MacFadyen ⁴, Fengxin Lu ⁴, Chang Xu ⁴, Elizabeth Karlson ⁴ and Paul Ridker ², ¹Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Harvard Medical School - Boston, MA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Liver test abnormalities are known to predict liver pathology in patients using methotrexate (MTX). Monitoring guidelines for MTX suggest frequent assessment of liver tests…
Abstract Number: 2358 • 2019 ACR/ARP Annual Meeting
Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials
Margaux MALAURIE¹, Arnaud Constantin ², Yannick Degboé ¹, Adeline Ruyssen-Witrand ³ and Thomas Barnetche ⁴, ¹CHU TOULOUSE, TOULOUSE, France, ²CHU TOUOUSE, TOULOUSE, France, ³Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, ⁴FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France
Background/Purpose: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or venous thromboembolic events (VTEs) in patients with rheumatoid arhthritis…
Abstract Number: 2359 • 2019 ACR/ARP Annual Meeting
High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis
Ori Elkayam ¹, Merav Lidar ², Tatiana Reitblat ³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Odelia Kakakian ¹, Tanya Meshiach ⁵, Ronit Almog ⁶ and Ofir Elalouf¹, ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Rheumatology Unit Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶the7Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel
Background/Purpose: The primary objective was to evaluate the effect of body mass index (BMI) on tumor necrosis factor α (TNF-α) blockers (including etanercept, infliximab, adalimumab…
Abstract Number: 2360 • 2019 ACR/ARP Annual Meeting
Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis
Silvana Saavedra¹, Karen Vergara ², Claudia Hernandez ², Pedro Zamorano ², Annelise Goecke ², Luis Toro ² and FELIPE REYES ¹, ¹HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Chile, ²HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Region Metropolitana, Chile
Background/Purpose: Interstitial lung disease (ILD) is a common pulmonary manifestation of rheumatoid arthritis (RA) that may be related to the inflammatory process itself, to infectious…
Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez ¹, Naydi Pérez-Ríos ¹, Noelia Rodríguez ¹, Grissel Ríos ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…
Abstract Number: 2362 • 2019 ACR/ARP Annual Meeting
Associations of Disease-Modifying Anti-Rheumatic Drug (DMARD) Adherence with Time to First Biologic and Cycle Time on DMARDs, and Healthcare Utilization/Cost in a New RA Patient Cohort
Stephanie Saeli¹, Joseph Roots ², Kelly Shields ² and Tarun Sharma ¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Data Science, Pittsburgh
Background/Purpose: Lack of adherence to medications is a well-known problem with chronic conditions, RA included. Nonadherence is associated with decreased quality of life and poorer…
Abstract Number: 2363 • 2019 ACR/ARP Annual Meeting
Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy
Eugenio Chamizo Carmona¹, Carmen carrasco-Cubero ², Sara María Rojas Herrera ¹, María Eugenia Gonzalez Naranjo ², Juan José Aznar Sanchez ³, Raul Veroz Gonzalez ¹, Pedro Dorado ² and Adrian LLerena Ruiz ², ¹Hospital de Mérida, Mérida, Spain, ²CHU de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida
Background/Purpose: Rheumatoid arthritis (RA) produces joint destruction, functional deterioration, comorbidity and premature death. The best results are achieved with an early start of a treat-to-target…
Abstract Number: 2364 • 2019 ACR/ARP Annual Meeting
Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development
Yoshihiko Hoshida¹, Shiro Ohshima ², Yukihiko Saeki ³, Masao Katayama ⁴, Tomoya Miyamura ⁵, Atsuahi Hashimoto ⁶, Shinji Higa ⁷, Hisaji Oshima ⁸, Masato Yagita ⁹, Yasushi Hiramatsu ¹⁰, Norie Yoshikawa ¹¹, Akiko Mitsuo ¹², Akira Okamoto ¹³, Noriyuki Chiba ¹⁴, Takao Sugiyama ¹⁵, Shouhei Nagaoka ¹⁶, Shoji Sugii ¹⁷, Keigo Setoguchi ¹⁸, Asami Abe ¹⁹, Toshiaki Sugaya ²⁰, Masahiro Koseto ²¹, Yasuo Kunugiza ²², Ryousuke Yoshihara ²³, Shinichiro Tsunoda ²⁴, Tomoaki Fujisaki ²⁵, Hiroshi Furukawa ²⁶, Kazuyoshi Saito ²⁷, Kiyoshi Matsui ²⁸, Yasuhiko Tomita ²⁹ and Shigeto Tohma ³⁰, ¹National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan, ²NHO Osaka Minami Medical Canter, Kawachinagano, Osaka, Japan, ³NHO Osaka Minami Medical Center, Kawachinagano, Osaka, Japan, ⁴National Hospital Organization Nagoya Medical Center, Nagoya, Japan, ⁵NHO Kyusyu Medical Center, Fukuoka, Japan, ⁶NHO Sagamihara Hospital, Sagamihara, Japan, ⁷Osaka Second Police Hospital, Osaka, Japan, ⁸NHO Tokyo Medical Hospital, Tokyo, Japan, ⁹Kitano Hospital, Osaka, Japan, ¹⁰Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan, ¹¹NHO Miyakonojo Medical Center, Miyakonojo, Miyazaki, Japan, ¹²NHO Disaster Medical Center, Tokyo, Tokyo, Japan, ¹³National Hospital Organization HImeji Medical Center, Himeji, Hyogo, Japan, ¹⁴National Hospital Organization Morioka Medical Center, Morioka, Iwate, Japan, ¹⁵NHO Shimoshizu Hospital, Chiba, Chiba, Japan, ¹⁶Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan, ¹⁷Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, ¹⁸Tokyo Metropolitan Cancer and Infectious Dease Center Komagome Hospital, Tokyo, Tokyo, Japan, ¹⁹Niigata Rheumatic Center, Shibata, Niigata, Japan, ²⁰Fuchu Hospital, Izumi, Osaka, Japan, ²¹Nippon Life Hospital, Osaka, Osaka, Japan, ²²JCHO Hoshigaoka Medical Center, Katano, Osaka, Japan, ²³Hyogo Prefecture Kakogawa Hospital, Kakogawa, Hyogo, Japan, ²⁴Sumitomo Hospital, osaka, Osaka, Japan, ²⁵Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan, ²⁶Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ²⁷University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁸Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²⁹International University of health and welfare, Narita, Chiba, Japan, ³⁰National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: Lymphoproliferative disorders (LPD) remains as a major problem to resolve among the patients with rheumatoid arthritis (RA). During few decades, rheumatic therapy has dramatically…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].